theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Endocrinology

Prostate Cancer   

Questions discussed in this category


Do you use denosumab for castration-sensitive prostate cancer with osseous metastases?
Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...
4 Answers available

When is the best time to start denosumab in men with metastatic prostate cancer?
Should it be started at the initial diagnosis of bone mets?
2 Answers available

Should bone-directed agents, such as denosumab or zoledronic acid, be given when patients are being treated with radium-223?
1 Answer available
1250606839


Papers discussed in this category


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Lancet, 2016 Mar 19
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Eur. Urol.,
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Related Topics in Endocrinology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Genitourinary Cancers
  • Melanoma/Skin Cancer

Copyright © 2025 theMednet
All Rights Reserved.